Lipoprotein (a)

Alberico L. Catapano, Magdalena Daccord, Elaine Damato, Steve E. Humphries, R. Dermot G. Neely, Børge G. Nordestgaard, Michele Pistollato, Elisabeth Steinhagen-Thiessen. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis, 2022

Burgess, S., Ference, B et al (2018) Association of LPA variants with risk of coronary disease and the implications for Lipoprotein (a) lowering therapies: A mendelian randomization analysis.  JAMA Cardiology. 3. 7. pp 619-672.  Full review available

O'Donoghue, M. et al (2019) Lipoprotein (a), PCSK9 inhibition and Cardiovascular Risk: Insights from the FOURIER Trial.  Circulation.  Vol 139, No 12. pp1483-1492.  Abstract available here

Pare, G et al (2019) Lipoprotein (a) Levels and the Risk of Myocardial Infarction among 7 Ethnic Groups.  Circulation. Vol 138. No 12. pp1472-1482.  Abstract available here

Thanassoulis, G. (2019) Editorial.  Screening for High Lipoprotein (a).  The Time is Now.  Circulation. Vol 139. pp1493-1496.  Full editorial available here